Cargando…
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care‐based interventions. Opioid‐based therapies underpin pain care in EB; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannab...
Autores principales: | Schräder, N.H.B., Duipmans, J.C., Molenbuur, B., Wolff, A.P., Jonkman, M.F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379189/ https://www.ncbi.nlm.nih.gov/pubmed/30347109 http://dx.doi.org/10.1111/bjd.17341 |
Ejemplares similares
-
Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?
por: Baardman, R., et al.
Publicado: (2020) -
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study
por: Schräder, Nicholas H. B., et al.
Publicado: (2021) -
Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index
por: Schräder, Nicholas H. B., et al.
Publicado: (2021) -
The C4EB study—Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
por: Schräder, Nicholas H. B., et al.
Publicado: (2022) -
Epidermolysis Bullosa Acquisita: The 2019 Update
por: Koga, Hiroshi, et al.
Publicado: (2019)